This Government Contract opportunity was posted on August 26, 2019. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Radiopharmacueticals

Closed

W81K00-19-Q-0296Federal

Submission Closed08/29/2019, 08:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

DIBBS

Supplier of Red Sealing Compound (NSN 8030015650423)

Defense Logistics Agency

POSTED

DEADLINE

Active Pharmaceutical Ingredient (API) SupplyThis subcontract for Active Pharmaceutical Ingredient (API) Supply involves the synthesis, purification, and bulk delivery of pharmaceutical-grade Benzocaine and Menthol. The provider supports prime contractors fulfilling requirements for the Department of Defense Medical Supply Chain Pharm FSA, ensuring all raw chemical components meet strict USP and ISO manufacturing standards through the use of HPLC purity testing. The performance of this contract is centered at Fort Campbell, Kentucky, under NAICS code 325412. The solicitation was posted on October 19, 2026, with a response deadline of October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Benzocaine and Menthol Lozenge SupplyThis subcontract involves the manufacture and supply of finished Benzocaine and Menthol lozenges to prime contractors supporting the Department of Defense Medical Supply Chain Pharm FSA. The provider is responsible for producing and quality-testing pharmaceutical lozenges within FDA-compliant facilities adhering to Good Manufacturing Practice standards to ensure all delivered quantities meet strict government specifications. Administrative processes for this requirement are managed through the DLA Internet Bid Board System for quote submissions. The performance of the contract is centered at Fort Campbell, and the procurement falls under NAICS code 325412 for pharmaceutical preparation.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Moxifloxacin Hydrochloride Tablets (400 MG)This subcontract, managed by the Medical Supply Chain Pharm FSA under the Department of Defense, involves the manufacture and supply of pharmaceutical-grade Moxifloxacin Hydrochloride Tablets (400 MG). The contractor is responsible for providing the antibiotic tablets in 30-count bottles, ensuring all products are sourced or manufactured in accordance with Good Manufacturing Practices and FDA approval and registration requirements. Logistical compliance is critical, as the contract mandates adherence to RP001 DLA Packaging Requirements and the use of climate-controlled storage and transport to maintain product integrity. Performance will take place in FPO 09591, with the primary objective of supporting prime contractors on DLA supply contracts.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Activated Charcoal, SuspensionThis subcontract, issued by the Medical Supply Chain Pharm FSA under the Department of Defense, requires the provision of activated charcoal in suspension form, identified by NSN 6505012828880. The materials must be delivered to the USS Lewis B Puller ESB 3, with all shipments adhering to strict DLA packaging requirements and technical specifications. The contract falls under NAICS code 325412 and is intended for prime contractors supporting DLA supply operations. Resellers are specifically required to comply with the Non-Manufacturer Rule to ensure eligibility. The performance location is designated as FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of 4% Chlorhexidine Gluconate Surgical DetergentThis subcontract involves the supply of FDA-regulated 4% Chlorhexidine Gluconate surgical detergent for prime contractors supporting Department of Defense supply contracts. The provider is responsible for manufacturing or sourcing the chemical compound in strict accordance with NSN 6505-01-101-3759 specifications and DLA Packaging Requirements RP001. To maintain quality and regulatory compliance, the product must be produced in FDA-approved pharmaceutical manufacturing facilities. The contract mandates a total shelf life of 24 months, with a requirement that the detergent possesses at least 21 months of remaining shelf life at the time of delivery. Managed under the Medical Supply Chain Pharm FSA, the performance of this contract is centered in FPO 96660, falling under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Bupivacaine and Epinephrine InjectionThis subcontract involves the supply of Bupivacaine and Epinephrine Injection to prime contractors supporting DLA Troop Support medical supply contracts. The provider must deliver end items compliant with NSN 6505-01-189-3973, utilizing pharmaceutical-grade materials and medical-grade packaging. To qualify, the supplier is required to hold all necessary pharmaceutical manufacturing licenses and maintain FDA approval for the specific drug formulation. Managed by the Department of Defense under the Medical Supply Chain Pharm FSA, the contract specifies the delivery of injectable medication quantities as outlined in the award. The performance location is designated as FPO 09591, and the procurement falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Isoniazid Tablet ManufacturingThis subcontract involves the manufacturing of Isoniazid 300 MG tablets for prime contractors supporting Department of Defense pharmaceutical supply contracts through the Medical Supply Chain Pharm FSA. The manufacturer is responsible for producing tablets that conform to United States Pharmacopeia standards, packaged in bottles of 100 units. To execute this contract, the provider must utilize pharmaceutical grade API, specialized tablet pressing equipment, and a USP-compliant quality control laboratory. Strict regulatory adherence is required, including the maintenance of active FDA registration and continuous USP compliance. The performance of this contract is centered in FPO 09591, with the primary objective of delivering finished pharmaceutical products that meet all specified government quality and safety benchmarks.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Tetrahydrozoline Hydrochloride Ophthalmic Solution SupplierThis subcontract involves the supply of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (0.05%, 15 ML) to support prime contractors under DLA Troop Support medical supply contracts. The selected provider is responsible for manufacturing or sourcing the pharmaceutical solution in accordance with USP standards, utilizing sterile ophthalmic bottling and packaging. All operations must comply with FDA approval and registration requirements for pharmaceutical manufacturing. The contract is managed by the Department of Defense under the Medical Supply Chain Pharm FSA. Physical deliveries of the ophthalmic solution are to be made to either the prime contractor or the Naval Med Readiness Logistics Command, with the place of performance located in Williamsburg, Virginia.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Tolnaftate Powder, USP 1%This subcontract through the Department of Defense Medical Supply Chain Pharm FSA involves the supply of Tolnaftate Powder, USP 1%, to prime contractors on DLA Troop Support medical supply contracts. The requirement is for 15 bottles of 45 GM powder, identified by NSN 6505014807897, which must strictly adhere to USP 1% standards and the DLA Master List of Technical and Quality Requirements. Eligible providers must possess the necessary pharmaceutical manufacturing and distribution licenses to fulfill the order. The performance of this contract is designated for FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Solicitation # SPE2DP-27-T-0122

Solicitation SPE2DP-27-T-0122 is a procurement request by the Defense Logistics Agency for surgical detergent containing 4% chlorhexidine gluconate, identified by NSN 6505-01-101-3759. The requirement is for one 8 oz bottle to be delivered FOB Destination to the USNS ABLE TAGOS 20. The item is FDA regulated and must have a total shelf life of 24 months, with at least 21 months remaining upon delivery to the government. The original required delivery date is October 21, 2026, with a delivery lead time of 20 days after award. The contract mandates strict adherence to Medical Marking Standard No. 1C and DLA packaging requirements RP001. Packaging must be commercial, utilizing sealed unit containers and suitable exterior shipping containers. If the material is deemed hazardous per FED-STD-313, it must follow TQ requirement IP025; otherwise, it must comply with ASTM D3951. Offerors must submit quotes via DIBBS by October 26, 2026, and provide a Safety Data Sheet meeting 29 CFR 1910.1200(g) prior to award. The procurement is subject to destination inspection under FAR 52.246-2 and incorporates the Buy American Act and HUBZone price evaluation preferences. Invoicing and receiving reports must be processed through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TETRAHYDROZOLINE HYDRO

Solicitation # SPE2DP-27-T-0130

Solicitation SPE2DP-27-T-0130 is a fixed-price contract issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the procurement of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (NSN 6505-00-139-4600). The requirement consists of one bottle of 0.05 percent, 15 ml solution, to be delivered FOB Destination to the Naval Med Readiness Logistics Cmd in Williamsburg, Virginia, with a required delivery date of October 21, 2026. The item is classified as a Type I (Code Q) item with a non-extendable shelf life of 36 months. The contract mandates strict adherence to commercial packaging standards, requiring sealed unit containers and exterior shipping containers that protect contents from damage. All materials must be marked according to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and preservation must comply with MIL-STD-2073-1E and special packaging instructions MPWN00001. Additionally, the contractor must comply with FDA regulations, the Buy American and Balance of Payments Program, and specific hazardous material labeling requirements under 29 CFR 1910.1200. Inspection and acceptance will occur at the destination point. Invoicing and payment are to be processed electronically through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 6 days

General Info

Agency

N/A

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

Fort Sam Houston, TX, 78234, USA

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed

PostedAug 26

special-notice

Response DeadlineAug 29

Deadline has passed

Submission Closed

08/29/2019, 08:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyN/A

Contacts2 people available

OfficeN/A

Organization / Agency

N/A

Office AddressN/A

Contacts

James MetzgerPurchasing Agent

contact@example.gov

+1 (555) 000-0000

Jamie BrunnerContracting Officer

contact@example.gov

+1 (555) 000-0000

Full Description

NOTICE OF INTENT: The Regional Health Contracting Office-Central, JBSA Fort Sam Houston, TX intends to award, on a Limiting Competition sole source basis, a firm-fixed priced contract to Cardinal Health 414 LLC. for supplying radiopharmaceuticals. The proposed North American Industry Classification System (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing, Product Service Code (PSC) 6505, Drugs and Biologicals with a corresponding size standard of 1,250 employees. The proposed contract action for which the Government intends to solicit from and award to one source is in accordance with FAR 13.106-1(b)(1). The Government intends to execute this award on or around 30 Aug 2019 for a 12 month period. This notice is neither a request for quotation nor a solicitation of offers; however, all responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency for any future requirements.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS